Acyclovir

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more

Treatment

20 Active Studies for Acyclovir

What is Acyclovir

Acyclovir

The Generic name of this drug

Treatment Summary

Acyclovir is a medication used to treat a variety of infections caused by the herpes virus, including herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis. It was first approved by the FDA in 1982 and can be prescribed to patients as young as 6 years old. Acyclovir is the most common first-line treatment for these types of viral infections.

Zovirax

is the brand name

image of different drug pills on a surface

Acyclovir Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zovirax

Acyclovir

1982

496

Effectiveness

How Acyclovir Affects Patients

Acyclovir is a drug that interrupts the replication of different kinds of herpes viruses. It’s very safe to use and is unlikely to cause an overdose in healthy patients.

How Acyclovir works in the body

Acyclovir works by preventing virus cells from replicating. It does this by first being converted into a monophosphate form, then a diphosphate form, and finally a triphosphate form. The triphosphate form of acyclovir binds to the DNA of virus cells, stopping them from replicating and growing. In some cases, acyclovir is so powerful that it stops the virus' DNA polymerase enzyme from functioning, preventing the virus from replicating.

When to interrupt dosage

The suggested amount of Acyclovir is contingent upon the determined condition, including Cytomegalovirus Infections, serious Genital herpes and Herpes simplex type I reactivation. Dosage is additionally subject to the method of delivery (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous) referenced in the table beneath.

Condition

Dosage

Administration

Bone Marrow Transplant

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Neutropenia

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Chickenpox

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Communicable Diseases

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Immunocompromised

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Genitalis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Shingles

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Keratitis, Herpetic

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Cytomegalovirus Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Bell Palsy

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Encephalitis, Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

prophylaxis of HSV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension, Suspension - Oral, Injection, solution, Intravenous, Injection, solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Powder, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Tablet - Buccal, Oral; Topical, Kit, Kit - Oral; Topical, Tablet, delayed release, Ointment - Ophthalmic, Ophthalmic, Cutaneous, Ointment - Cutaneous

Warnings

Acyclovir Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Acyclovir may interact with Pulse Frequency

There are 20 known major drug interactions with Acyclovir.

Common Acyclovir Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Acyclovir.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Acyclovir.

Tenofovir

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.

Acyclovir Toxicity & Overdose Risk

Overdosing on Diclofenac can cause agitation, unconsciousness, seizures, extreme tiredness, and a buildup of substances in the kidneys. These symptoms are more likely to occur in patients who are given high doses without monitoring their fluid and electrolyte levels or having reduced kidney function. If an overdose occurs, it should be treated with supportive care.

image of a doctor in a lab doing drug, clinical research

Acyclovir Novel Uses: Which Conditions Have a Clinical Trial Featuring Acyclovir?

34 active clinical trials are currently being conducted to evaluate the potential of Acyclovir for preventing VZV reactivation, and in the treatment of Immunocompromised and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Encephalitis, Herpes Simplex

0 Actively Recruiting

Herpes Simplex Infections

0 Actively Recruiting

Herpes Genitalis

0 Actively Recruiting

VZV re-activation

0 Actively Recruiting

Chickenpox

4 Actively Recruiting

Phase 4, Phase 3

Neutropenia

4 Actively Recruiting

Phase 1, Phase 2, Phase 3

Cytomegalovirus Infections

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone Marrow Transplant

27 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Keratitis, Herpetic

0 Actively Recruiting

prophylaxis of HSV re-activation

0 Actively Recruiting

Shingles

4 Actively Recruiting

Phase 2, Phase 1

Herpes Simplex

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

prophylaxis of VZV re-activation

0 Actively Recruiting

Bell Palsy

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Acyclovir Reviews: What are patients saying about Acyclovir?

5

Patient Review

2/2/2019

Acyclovir for Cold Sore

I'm really impressed with this medication. It's stopped my cold sores from developing entirely. I would highly recommend it to others who suffer from the same problem.

5

Patient Review

8/25/2019

Acyclovir for Cold Sore

This medication is a lifesaver for me. I get cold sores frequently, and this speeds up the healing process by days or even weeks. I travel a lot, so it's great to have on hand wherever I go.

5

Patient Review

6/10/2021

Acyclovir for Shingles

I really hope that Acyclovir becomes cheaper so that more people can afford it and fight back against viruses.

5

Patient Review

7/29/2021

Acyclovir for Genital Herpes

Acyclovir has been great for me. I take it once a day and it really helps manage the symptoms of my disease.

5

Patient Review

10/19/2021

Acyclovir for Genital Herpes

I've been taking this medication daily as prescribed, and I haven't had any issues since.

5

Patient Review

3/30/2022

Acyclovir for Prevent Recurrent Herpes Simplex Infection

I kept getting recurrent episodes of labialis, but this treatment really cleared it up. It's more expensive than some other options, but it's worth it!

5

Patient Review

6/22/2022

Acyclovir for Cold Sore

I've been using this medication for cold sores for years, and it really works! I take two pills at the first sign of a sore, and then one pill per day for a week. This has helped me avoid painful and unsightly cold sores.

4.7

Patient Review

12/12/2019

Acyclovir for Genital Herpes

Since I started this medication when I was 18, it's been working great. For a while, I had constant breakouts; now that I take the medication every day, I have only a handful of breakouts each year--and they go away in three days at most! They're also less painful now.

4.3

Patient Review

9/9/2020

Acyclovir for Cold Sore

Acyclovir effectively cleared my cold sore, but it came back soon after I stopped taking it. A maintenance dose of 200mg 3x per day didn't do much. In my case, 400mg 3x per day was the sweet spot. Not sure how long I'll need to keep this up, because as soon as I stop, the outbreak returns - often worse than it was before.

4

Patient Review

9/11/2019

Acyclovir for Genital Herpes

Acyclovir has been a godsend for me. I've been on it for over a year to manage my symptoms, and it's been incredibly effective. I will say, though, that you need to be aware of the potential side effects before starting any kind of treatment like this.

4

Patient Review

5/20/2019

Acyclovir for Shingles

I am 61 years old and have been with shingles the first time. My doctor prescribed me 800mg 3xs a day for 7 days. With my first taking this drug, I felt sleepy, I like to sleep most of the time.I felt light-headedness, seems floating in the air, but I know what I am doing.I hope Acyclovir will work since it is my 2nd day taking it. The pain in my shingles seems reduced. But I am always have this sleepy moments and always like to eat and drink water.

2.3

Patient Review

8/7/2020

Acyclovir for Prevent Shingles in Patients Without a Normal Immune System

I was prescribed acyclovir as a prophylactic to prevent shingles. I have leukemia with low white blood cell count. I hated it from the getgo. This past week I thought I had UTI but test was negative. I have been taking OTC cystex to prevent pain. There was blood in my urine which is listed as a more severe side effect of this drug. I am going off it immediately due to the potential kidney damage and other adverse effects on my health.

2.3

Patient Review

7/7/2022

Acyclovir for Prevent Shingles in Patients Without a Normal Immune System

I got Shingles and my doctor put me on Acyclovir-oral. After the second pill I broke out in a rash. Then he tried another medicine from the same family and again I broke out again. So I wanted to try the cream. But having trouble in getting my doctor to order it for me. I know one thing, That is when I get over it I am getting the shingles shots. Because Twice is enough for me.

2.3

Patient Review

8/7/2020

Acyclovir for Prevent Shingles in Patients Without a Normal Immune System

I was prescribed acyclovir as a prophylactic to prevent shingles. I have leukemia with low white blood cell count. I hated it from the getgo. This past week I thought I had UTI but test was negative. I have been taking OTC cystex to prevent pain. There was blood in my urine which is listed as a more severe side effect of this drug. I am going off it immediately due to these concerning kidney and blood effects..
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about acyclovir

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of taking acyclovir daily?

"Symptoms of the flu can include an upset stomach, vomiting, diarrhea, dizziness, and tiredness. In more severe cases, people may experience agitation and pain, especially in the joints. Some people also report hair loss as a symptom of the flu."

Answered by AI

What is acyclovir used to treat for?

"UK

Aciclovir is a medicine that is used to treat cold sores, chickenpox and shingles. It is available as a cream or as a tablet."

Answered by AI

Can you buy acyclovir over the counter?

"Can you buy Aciclovir without a prescription? No – a doctor or pharmacist must prescribe Aciclovir for you. However, you can consult with a healthcare professional online at The Independent Pharmacy to get Aciclovir."

Answered by AI

How long does it take for acyclovir to work?

"Effects may not be seen for up to two hours after taking acyclovir, but the drug should be taken until the course prescribed is finished. Acyclovir is most effective when started within 48 hours of the start of symptoms."

Answered by AI

Clinical Trials for Acyclovir

Image of Princess Margaret Cancer Centre, University Health Network in Toronto, Canada.

Psychoeducation for Caregivers of Bone Marrow Transplant Patients

18+
All Sexes
Toronto, Canada

Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being. This study aims to evaluate the feasibility and acceptability of an adapted psychoeducational intervention(PEI) designed to support these caregivers. Methods: This study will recruit caregivers of alloHCT patients. Participants will be enrolled during pre-transplant clinic visits, typically 2-4 weeks before the scheduled transplant. The intervention consists of eight sessions over 12 weeks, delivered via Microsoft Teams by a nurse facilitator. In the adapted PEI, participants will learn stress management, coping strategies, energy management, goal-setting, communication skills, and support resource access through interactive exercises. Data Collection: Participants will complete questionnaires at three time points: pre-intervention, one month post-transplant, and three months post-transplant. The final assessment will include additional questions about feasibility, acceptability and the initial efficacy of the adapted PEI. Outcomes: The primary outcomes will be the feasibility and acceptability of the adapted psychoeducational intervention (PEI). Secondary outcomes will include initial efficacy of the adapted PEI on caregiver outcomes such as depression, anxiety, satisfaction with caregiving and quality of life. Significance: This research aims to assess the feasibility, acceptability and initial efficacy of implementing the adapted PEI for alloHCT caregivers. If found feasible and acceptable, this intervention could potentially improve caregivers' ability to manage caregiving stressors and pave the way for larger-scale randomized studies and implementation.

Recruiting
Has No Placebo

Princess Margaret Cancer Centre, University Health Network

Samantha Mayo, RN, PhD

Image of Georgetown University School of Medicine in Washington, United States.

Mosaic Website for Blood Cancer Patients

18+
All Sexes
Washington, United States

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Recruiting
Has No Placebo

Georgetown University School of Medicine (+3 Sites)

Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS

The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study

Waitlist Available
Has No Placebo

University of Kansas Cancer Center (+2 Sites)

Anthony Sung, MD

Have you considered Acyclovir clinical trials?

We made a collection of clinical trials featuring Acyclovir, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Acyclovir clinical trials?

We made a collection of clinical trials featuring Acyclovir, we think they might fit your search criteria.
Go to Trials
Image of Dana-Farber Cancer Institute in Boston, United States.

Digital Support for Bone Marrow Transplant

18+
All Sexes
Boston, MA

The overall goal of this study is to assess the efficacy of the care.coach Avatar™ in improving anxiety and quality of life for patients undergoing outpatient transplant. After care.coach Avatar™ content and scheduling ("digital intervention" or "program") has been optimized for outpatient allogeneic hematopoietic stem cell transplantation (HCT), a randomized controlled trial (RCT) will be conducted of the digital versus usual supportive care program for outpatient HCT recipients. Potential improvements in anxiety and quality of life will be evaluated, with the intent of increasing comfortability with outpatient transplant and expanding the population of eligible patients willing to receive their transplants in an outpatient setting.

Recruiting
Has No Placebo

Dana-Farber Cancer Institute

Victor Wang, MS

Friendi.fi Corporation

Have you considered Acyclovir clinical trials?

We made a collection of clinical trials featuring Acyclovir, we think they might fit your search criteria.
Go to Trials